<DOC>
	<DOCNO>NCT02453256</DOCNO>
	<brief_summary>This study ass efficacy safety tocilizumab compare placebo participant SSc across approximately 120 global study site . The study consist 48-week , double-blind , placebo-controlled period follow 48-week open-label treatment period .</brief_summary>
	<brief_title>A Study Efficacy Safety Tocilizumab Participants With Systemic Sclerosis ( SSc ) focuSSced</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>At least 18 year age Diagnosis systemic sclerosis ( SSc ) accord American College Rheumatology ( ACR ) European League Against Rheumatism ( EULAR ) Criteria , meet criterion active disease total disease duration less equal 60 month Modified Rodnan Skin Score ( mRSS ) 10 35 unit , inclusive Agreement remain abstinent use effective contraceptive method among male female childbearing potential Pregnant lactating female Major surgery within 8 week prior screen Scleroderma limit area distal elbow knee Rheumatic autoimmune disease SSc Immunization live attenuate vaccine within 4 week prior Baseline Known hypersensitivity human , humanize , murine monoclonal antibody Moderately severe nervous system , renal , endocrine , pulmonary , cardiovascular , gastrointestinal ( GI ) disease relate SSc , include diverticulitis ulcerative low GI disorder , myocardial infarction ( MI ) within 6 month prior screen Active significant history infection , include treatment intravenous ( IV ) antibiotic within 4 week oral antibiotic within 2 week prior screen Significant history tuberculosis ( TB ) Primary secondary immunodeficiency Malignant disease , exception excised/cured local basal squamous cell carcinoma skin carcinoma situ uterine cervix History drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>